131 related articles for article (PubMed ID: 29050203)
1. Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia.
Maifrede S; Magimaidas A; Sha X; Mukherjee K; Liebermann DA; Hoffman B
Oncotarget; 2017 Sep; 8(41):69281-69294. PubMed ID: 29050203
[TBL] [Abstract][Full Text] [Related]
2. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
[TBL] [Abstract][Full Text] [Related]
3. Loss of Gadd45b accelerates BCR-ABL-driven CML.
Sha X; Hoffman B; Liebermann DA
Oncotarget; 2018 Sep; 9(70):33360-33367. PubMed ID: 30279966
[TBL] [Abstract][Full Text] [Related]
4. BCR/ABL can promote CD19
Li D; Zhao X; Zhang R; Jiao B; Liu P; Ren R
Stem Cell Investig; 2016; 3():85. PubMed ID: 28066787
[TBL] [Abstract][Full Text] [Related]
5. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
6. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.
Krause DS; Lazarides K; von Andrian UH; Van Etten RA
Nat Med; 2006 Oct; 12(10):1175-80. PubMed ID: 16998483
[TBL] [Abstract][Full Text] [Related]
7. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
8. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
Peng C; Li S
Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
[TBL] [Abstract][Full Text] [Related]
9. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
10. Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia.
William BM; Goodrich A; Peng C; Li S
Hematology; 2008 Dec; 13(6):333-43. PubMed ID: 19055861
[TBL] [Abstract][Full Text] [Related]
11. Expression of BCR - ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation.
Cambier N; Zhang Y; Vairo G; Kosmopoulos K; Metcalf D; Nicola NA; Elefanty AG
Oncogene; 1999 Jan; 18(2):343-52. PubMed ID: 9927191
[TBL] [Abstract][Full Text] [Related]
12. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
[TBL] [Abstract][Full Text] [Related]
13. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
14. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
16. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Danisz K; Blasiak J
Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
[TBL] [Abstract][Full Text] [Related]
17. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
Lin H; Monaco G; Sun T; Ling X; Stephens C; Xie S; Belmont J; Arlinghaus R
Oncogene; 2005 May; 24(20):3246-56. PubMed ID: 15735695
[TBL] [Abstract][Full Text] [Related]
18. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.
Scheicher R; Hoelbl-Kovacic A; Bellutti F; Tigan AS; Prchal-Murphy M; Heller G; Schneckenleithner C; Salazar-Roa M; Zöchbauer-Müller S; Zuber J; Malumbres M; Kollmann K; Sexl V
Blood; 2015 Jan; 125(1):90-101. PubMed ID: 25342715
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
[TBL] [Abstract][Full Text] [Related]
20. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.
Gishizky ML; Johnson-White J; Witte ON
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3755-9. PubMed ID: 8475126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
